Habu Daiki, Nishiguchi Shuhei, Nakatani Shinji, Kawamura Etsuji, Lee Chulyoo, Enomoto Masaru, Tamori Akihiro, Takeda Tadashi, Tanaka Takashi, Shiomi Susumu
Department of Hepatology, Graduate School of Medicine, Osaka City University Medical School, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, 545-8585, Osaka, Japan
Hepatol Res. 2003 Mar;25(3):312-318. doi: 10.1016/s1386-6346(02)00267-x.
We designed a randomized pilot trial to examine whether increase or preservation of serum albumin levels was attained with earlier administration of branched-chain amino acid (BCAA) granules for cirrhosis in grade A according to Child-Pugh classification using branched-chain tyrosine ratio (BTR) as an indicator. Forty patients with HCV-related cirrhosis in grade A with serum albumin level between 3.5 and 3.9 g/dl were enrolled in this study. Half of the patients were randomly assigned to receive 14.3 g/day of BCAA granules orally, and half were assigned to a control. Patients were evaluated at entry and at 1-year interval for at least 2 years. For patients whose BTR was less than 4.0, mean change in serum albumin in the BCAA group was significantly higher than that in the control group after 1 and 2 years of treatment. However, for patients whose BTR was more than 4.0, mean change in serum albumin in the BCAA group was not significantly higher than that in the control group after 1 and 2 years of treatment. In conclusion, early oral supplementation of BCAA for HCV-related cirrhosis with serum albumin level between 3.5 and 3.9 g/dl and BTR less than 4.0, improves serum albumin levels and thus might improve prognosis.
我们设计了一项随机对照试验，以检验对于根据Child-Pugh分类为A级的肝硬化患者，以支链酪氨酸比值（BTR）为指标，早期给予支链氨基酸（BCAA）颗粒是否能提高或维持血清白蛋白水平。本研究纳入了40例血清白蛋白水平在3.5至3.9 g/dl之间的丙型肝炎病毒相关A级肝硬化患者。其中一半患者被随机分配口服每日14.3 g的BCAA颗粒，另一半作为对照组。在入组时以及之后至少2年的时间里，每隔1年对患者进行评估。对于BTR小于4.0的患者，治疗1年和2年后，BCAA组血清白蛋白的平均变化显著高于对照组。然而，对于BTR大于4.0的患者，治疗1年和2年后，BCAA组血清白蛋白的平均变化并不显著高于对照组。总之，对于血清白蛋白水平在3.5至3.9 g/dl且BTR小于4.0的丙型肝炎病毒相关肝硬化患者，早期口服补充BCAA可提高血清白蛋白水平，从而可能改善预后。
